Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms

SARS-CoV-2 Neutralizing Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Correlation With Immunity and Long-COVID-19 Symptoms

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05484700

Enrollment

305

Registered

2022-08-02

Start date

2021-12-30

Completion date

2022-12-29

Last updated

2022-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long COVID-19

Keywords

Long COVID-19, antibody responsibility, immunogenicity

Brief summary

We investigated the association between immune system responsibilities in Long COVID patients and Full recovery patients.

Detailed description

This retrospective cohort study compared immunogenicity post COVID-19 between individuals (aged 18-65 years and had confirmed SARS-CoV-2 infection from January to May 2022 ) with residual Long COVID-19 symptoms (LC) and ones with full recovery (Full) related to pathophysiology, immunology and clinical consequence.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Long COVID group; at longer than 1-month post COVID-19 based the presence of one of the three following symptoms: fatigue/myalgia, breathlessness, and anorexia * Full recovery group; patients with asymptomatic symptoms * post COVID-19 they had not received any additional COVID vaccine

Exclusion criteria

* people who received additional vaccination after leaving quarantine before the day of the immunization test * pregnant patients, * people who had a history of allergic reactions after COVID-19 vaccination or any drugs

Design outcomes

Primary

Measure	Time frame	Description
Anti-SARS-CoV-2 RBD IgG	Baseline	anti-SARS-CoV-2 receptor-binding domain immunoglobulin G(BAU/mL)
Anti-SARS-CoV-2 NP	Baseline	surrogate Virus Neutralization Test (sVNT) (PRNT50 titer)
Microneutralization assays	Baseline	Microneutralization assays using the authentic SARS-CoV-2 viruses

Secondary

Measure	Time frame	Description
Number of vaccine injection	Baseline	Number of vaccine injection
Prevalence of Long COVID-19 symptoms	Baseline	Number of participants with major Long COVID-19 symptoms including fatigue/myalgia, breathlessness, and anorexia by using the questionnaire

Countries

Thailand

Outcome results